title: Commentary on "Statistical Approaches to Assess Biosimilarity from Analytical Data" by Burdick et al[1].
authors.affiliation: US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA. Yi.Tsong@fda.hhs.gov.
authors.forename: Yi
authors.initials: Y
authors.lastname: Tsong
authors.affiliation: Temple University, 1801 N Broad St, Philadelphia, Pennsylvania, 19122, USA.
authors.forename: Qi
authors.initials: Q
authors.lastname: Xia
authors.affiliation: US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA.
authors.forename: Yu-Ting
authors.initials: YT
authors.lastname: Weng
mesh_terms: D059451:Biosimilar Pharmaceuticals; D006801:Humans; D013810:Therapeutic Equivalency
chemical_list: D059451:Biosimilar Pharmaceuticals
keywords: biosimilarity; variance component model